

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT

FURTHER SHARE PURCHASE FOR SHARE AWARD SCHEME

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis.

Reference is made to the Post-IPO Share Award Scheme of the Company (the “**Scheme**”) adopted by the Company on June 10, 2022 and the voluntary announcement of the Company dated January 10, 2024 in relation to share purchase for the Scheme.

The board of directors of the Company (the “**Board**”) is pleased to announce that pursuant to the trust arrangements entered into between the Company and the trustee of the Scheme (the “**Trustee**”), the Trustee has further purchased on-market of a total of 1,087,700 shares of the Company (the “**Shares**”) for the purpose of satisfying the grant of awards under the Scheme. Details of the purchases by the Trustee in January 2024 are as follows:

Purchase period:	January 2, 2024 to January 17, 2024
Total number of Shares purchased:	1,287,700
Percentage of Shares purchased to the existing total number of Shares in issue:	Approximately 0.22%
Range of average consideration ^(note) per Share:	Approximately HK\$5.85 to approximately HK\$6.54
Total consideration of Shares purchased:	Approximately HK\$7,997,701

Note:

Average consideration = Total consideration for Shares purchased of the trading day/Total Shares purchased during the trading day

Pursuant to the trust arrangement, the Trustee shall hold on trust and manage the funds and properties for the benefit of the selected participants of the Scheme in accordance with the Scheme and the trust arrangement (the “**Trust Fund**”). The Shares purchased will form part of the Trust Fund and will be held by the Trustee on trust for the benefit of the selected participants of the Scheme. Subject to and in accordance with the Scheme and the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Board or its authorized persons will from time to time review and determine at its absolute discretion such number of Shares to be awarded to the Eligible Persons (as defined in the Scheme) with such vesting conditions as it may deem appropriate.

The Board believes that the on-market share purchases pursuant to the Scheme signifies the Company’s confidence in the long-term growth prospects of the Company and also serves as part of the Company’s strategy to attract talents and align the interests of key employees with the interests of the Company for the sustainable growth of the Group in the long term.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, January 17, 2024

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*